153 related articles for article (PubMed ID: 23537216)
1. Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.
Collier P; Patel K; Waeltz P; Rupar M; Luthra R; Liu PC; Hollis G; Huber R; Verstovsek S; Burn TC
Genet Test Mol Biomarkers; 2013 May; 17(5):429-37. PubMed ID: 23537216
[TBL] [Abstract][Full Text] [Related]
2. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
[TBL] [Abstract][Full Text] [Related]
3. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
[TBL] [Abstract][Full Text] [Related]
4. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
Bench AJ; White HE; Foroni L; Godfrey AL; Gerrard G; Akiki S; Awan A; Carter I; Goday-Fernandez A; Langabeer SE; Clench T; Clark J; Evans PA; Grimwade D; Schuh A; McMullin MF; Green AR; Harrison CN; Cross NC;
Br J Haematol; 2013 Jan; 160(1):25-34. PubMed ID: 23057517
[TBL] [Abstract][Full Text] [Related]
5. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
6. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
Takahashi K; Patel KP; Kantarjian H; Luthra R; Pierce S; Cortes J; Verstovsek S
Blood; 2013 Nov; 122(23):3784-6. PubMed ID: 24068492
[TBL] [Abstract][Full Text] [Related]
7. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
[TBL] [Abstract][Full Text] [Related]
8. Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting.
Lin CY; Ho CM; Tamamyan G; Yang SF; Peng CT; Chang JG
J Clin Lab Anal; 2016 Nov; 30(6):838-844. PubMed ID: 27169616
[TBL] [Abstract][Full Text] [Related]
9. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
10. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.
Link-Lenczowska D; Pallisgaard N; Cordua S; Zawada M; Czekalska S; Krochmalczyk D; Kanduła Z; Sacha T
Ann Hematol; 2018 Dec; 97(12):2299-2308. PubMed ID: 30056580
[TBL] [Abstract][Full Text] [Related]
11. Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms.
Morishita S; Komatsu N; Kirito K; Koda AH; Sekiguchi Y; Tsuneda S; Noda N
Leuk Res; 2011 Dec; 35(12):1632-6. PubMed ID: 21752468
[TBL] [Abstract][Full Text] [Related]
12. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
[TBL] [Abstract][Full Text] [Related]
13. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
Ha JS; Kim YK; Jung SI; Jung HR; Chung IS
Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
[TBL] [Abstract][Full Text] [Related]
14. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
15. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.
Merker JD; Jones CD; Oh ST; Schrijver I; Gotlib J; Zehnder JL
J Mol Diagn; 2010 Jan; 12(1):58-64. PubMed ID: 19959796
[TBL] [Abstract][Full Text] [Related]
16. Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis.
Reading NS; Lim MS; Elenitoba-Johnson KS
Mol Diagn Ther; 2006; 10(5):311-7. PubMed ID: 17022694
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells.
Cheng Z; Fu J; Liu G; Zhang L; Xu Q; Wang SY
Leuk Lymphoma; 2018 Jan; 59(1):196-203. PubMed ID: 28554272
[TBL] [Abstract][Full Text] [Related]
18. Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms.
Fontanelli G; Baratè C; Ciabatti E; Guerrini F; Grassi S; Del Re M; Morganti R; Petrini I; Arici R; Barsotti S; Metelli MR; Danesi R; Galimberti S
Int J Lab Hematol; 2015 Dec; 37(6):766-73. PubMed ID: 26189968
[TBL] [Abstract][Full Text] [Related]
19. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
[TBL] [Abstract][Full Text] [Related]
20. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
